IP Library Granted Patent US 8,598,225
Granted Patent B2
US 8,598,225 · App. 12/908,520 · Granted Dec 3, 2013

Use of L-butylphthalide in the manufacture of medicaments for treatment of cerebral infarct

Inventors: Yipu Feng (Beijing, CN); Xiaoliang Wang (Beijing, CN); Jinghua Yang (Beijing, CN); Ying Peng (Beijing, CN)
Assignee: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,225
App. No.
12/908,520
Granted
Dec 3, 2013
Kind
B2
Abstract

The present invention discloses the use of L-butylphthalide of formula (I) in the manufacture of medicaments for the prevention and treatment of cerebral infarct, especially induced by focal cerebral ischemia.

Claims (6)

1. A method of using L-butylphthalide of formula (I) for reducing the volume of cerebral infarct in a subject suffering from cerebral infarct, comprising orally administering a therapeutically effective dose of L-butylphthalide of formula (I),

to the subject 15 minutes after ischemia to reduce the volume of the cerebral infarct.

2. The method of use according to claim 1 , wherein said cerebral infarct is induced by focal cerebral ischemia.

3. The method of use according to claim 1 , wherein the therapeutically effective dose of said L-butylphthalide is 0.1-100 mg/kg per day.

4. A method of using L-butylphthalide of formula (I) for improving neurological behavioral symptoms in a subject suffering from cerebral infarct, comprising orally administering a therapeutically effective dose of L-butylphthalide of formula (I),

to the subject 15 minutes after ischemia to improve the neurological behavioral symptoms induced by the cerebral infarct.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNOR AND NAME OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 031318 FRAME 0089. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 2, 2013
From: SHIJIAZHUANG PHARMA. GROUP ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
To: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
Reel/Frame 031448/0615 →
CHANGE OF NAME Recorded Oct 1, 2013
From: SHIJIAZHUANG PHARMA. GROUP ZHONGOI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
To: CSPC ZHONGOI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
Reel/Frame 031318/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2010
From: FENG, YIPU; WANG, XIAOLIANG; YANG, JINGHUA; PENG, YING
To: SHIJIAZHUANG PHARMA. GROUP ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.; INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Reel/Frame 025168/0244 →
Priority Claims (1)
CN 2003 1 0100222 · Oct 10, 2003 · national
Continuity (2)
Continuation 10574917
Related Publication 20110082201A1 · Apr 7, 2011